BR9912356A - Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato - Google Patents

Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato

Info

Publication number
BR9912356A
BR9912356A BR9912356-8A BR9912356A BR9912356A BR 9912356 A BR9912356 A BR 9912356A BR 9912356 A BR9912356 A BR 9912356A BR 9912356 A BR9912356 A BR 9912356A
Authority
BR
Brazil
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
administration
pharmaceutical composition
Prior art date
Application number
BR9912356-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw Burxynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw Burxynski filed Critical Stanislaw Burxynski
Publication of BR9912356A publication Critical patent/BR9912356A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9912356-8A 1998-07-23 1999-07-02 Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato BR9912356A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
BR9912356A true BR9912356A (pt) 2001-04-17

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912356-8A BR9912356A (pt) 1998-07-23 1999-07-02 Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato

Country Status (20)

Country Link
US (2) US6258849B1 (OSRAM)
EP (1) EP1098643B1 (OSRAM)
JP (2) JP2002521329A (OSRAM)
KR (4) KR100399658B1 (OSRAM)
CN (3) CN100400039C (OSRAM)
AT (1) ATE257378T1 (OSRAM)
AU (1) AU759278B2 (OSRAM)
BR (1) BR9912356A (OSRAM)
CA (1) CA2336945C (OSRAM)
DE (1) DE69914084T2 (OSRAM)
DK (1) DK1098643T3 (OSRAM)
EA (1) EA004179B1 (OSRAM)
ES (1) ES2214866T3 (OSRAM)
ID (1) ID28160A (OSRAM)
IL (1) IL140848A (OSRAM)
NZ (1) NZ509244A (OSRAM)
PL (1) PL213698B1 (OSRAM)
PT (1) PT1098643E (OSRAM)
WO (1) WO2000004894A2 (OSRAM)
ZA (1) ZA200100622B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
JP2008508300A (ja) * 2004-07-28 2008-03-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌剤としての３−ブロモ−２−オキソプロピオン酸プロピルおよび誘導体
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
IL270413B (en) 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes of making l-ornithine phenylacetate
IL272422B2 (en) * 2017-06-12 2025-03-01 R Burzynski Stanislaw Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
CA2254772C (en) 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
US6258849B1 (en) 2001-07-10
DE69914084T2 (de) 2004-10-28
CN1605334A (zh) 2005-04-13
HK1037142A1 (en) 2002-02-01
ZA200100622B (en) 2002-06-26
EP1098643B1 (en) 2004-01-07
CN1191064C (zh) 2005-03-02
WO2000004894A2 (en) 2000-02-03
NZ509244A (en) 2004-02-27
EA200100168A1 (ru) 2001-08-27
KR20030027088A (ko) 2003-04-03
PT1098643E (pt) 2004-05-31
KR100417100B1 (ko) 2004-02-05
CA2336945C (en) 2008-11-18
KR100414587B1 (ko) 2004-01-13
CN1319010A (zh) 2001-10-24
ID28160A (id) 2001-05-10
ES2214866T3 (es) 2004-09-16
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
IL140848A (en) 2005-05-17
KR20030027087A (ko) 2003-04-03
DE69914084D1 (de) 2004-02-12
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
JP2011051993A (ja) 2011-03-17
KR100417101B1 (ko) 2004-02-05
PL213698B1 (pl) 2013-04-30
US6943192B2 (en) 2005-09-13
ATE257378T1 (de) 2004-01-15
AU4854299A (en) 2000-02-14
CA2336945A1 (en) 2000-02-03
WO2000004894A3 (en) 2000-04-27
AU759278B2 (en) 2003-04-10
KR20030027089A (ko) 2003-04-03
EP1098643A2 (en) 2001-05-16
CN100400039C (zh) 2008-07-09
CN1660061A (zh) 2005-08-31
EA004179B1 (ru) 2004-02-26
DK1098643T3 (da) 2004-05-24
US20010044466A1 (en) 2001-11-22
PL345959A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
BR9912356A (pt) Regime de tratamento para a administração de fenilacetilglutamina, fenilacetilisoglutamina, e/ou fenilacetato
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
BR9812588A (pt) Métodos e composições farmacêuticas para liberação oral de iodo molecular
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
EA200501105A1 (ru) Фармацевтическая композиция
IL192287A0 (en) Pharmaceutical compositions and methods for use
KR970025615A (ko) 암 전이 억제제
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9912609A (pt) Métodos de uso de um análogo de somatostatina
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
IT1229271B (it) Preparazione medicinale di un estratto delle radici di ortica, urtica kiovensis (rogowicz), suo impiego per il trattamento di tumori e processo di preparazione.
RU2417091C2 (ru) Способ лечения артрозо-артритов
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
RU2003121205A (ru) Способ профилактики и (или) лечения анемии у детей (варианты)
KR880008813A (ko) 체내분비액중 위산과다증 치료약제 및 치료방법
MD2035F1 (en) Method of decreasing the vascular contraction induced by natural vasoconstrictor agents

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 13.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.